First Milestone Successfully Achieved in Ribo’s Collaboration in Liver Diseases With Boehringer Ingelheim
Suzhou Ribo Life Science and Ribocure AB are excited to share that we have achieved a key pre-clinical milestone in our siRNA programs, less than a year into our collaboration with Boehringer Ingelheim.
These achievements highlight the strength of Boehringer Ingelheim'sexpertise in MASH and validates the power of the Ribo platform and organization (click to view original news).
We are looking forward to advancing these and remaining ourcollaboration programs into 2025 and beyond to address high unmet patient needs.
We have rich pipeline
We are at the forefront of oligonucleotide drug innovation focused on cardiovascular, metabolic, renal diseases and liver diseases, as well as other therapeutic areas.